Array BioPharma Presents Additional Positive Phase 2 Results In Inflammatory Pain Clinical Trial At The American Pain Society’s Annual Scientific Meet
May 15th 2008Drug InformationDentistry
Array BioPharma Inc. (Nasdaq: ARRY) announced that its Chief Medical Officer, John Yates, M.D., presented additional positive results from a Phase 2 clinical trial evaluating the efficacy of ARRY-797, a novel small molecule pan-cytokine inhibitor, in patients with post-surgical dental pain at the American Pain Society’s 27th Annual Scientific Meeting in Tampa, Florida.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
